Product Information
OLOPATADINE 665 MCG NASAL SPRY is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.8495 per GM under NDC 45802010401. Its NADAC has been published 480 times since Jul 26, 2017.
FDA first approved this application on Jan 31, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
665 ug/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802010401
Classification
Generic
Dosage Form
SPRAY
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
OLOPATADINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA202853FDA Approved
1/31/2017
TE Code
AB
On Market Since
6/14/2017
Pharmacological Classes
Price Statistics
The NADAC for OLOPATADINE 665 MCG NASAL SPRY has been published 480 times since Jul 26, 2017, and over the history we have for it it has declined 80.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8495 per GM |
|---|---|
| All-time high | $4.8968 (Sep 13, 2017) |
| All-time low | $0.7522 (May 22, 2024) |
| 52-week high | $0.9411 |
| 52-week low | $0.8495 |
| Median price | $1.2385 |
| Average price | $1.7000 |
| Largest weekly change | +49.7% (Feb 21, 2018) |
| Weeks tracked | 480 |
| Tracking since | Jul 26, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Olopatadine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OLOPATADINE 665 MCG NASAL SPRY?
The current National Average Drug Acquisition Cost (NADAC) for OLOPATADINE 665 MCG NASAL SPRY, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.8495 per GM (NDC 45802010401), effective Sep 30, 2026.
How has the price of OLOPATADINE 665 MCG NASAL SPRY changed over time?
Over the history we have for it, the NADAC for OLOPATADINE 665 MCG NASAL SPRY has declined 80.6%. It has been tracked across 480 weekly CMS publications since Jul 26, 2017.
What are the highest and lowest recorded NADAC prices for OLOPATADINE 665 MCG NASAL SPRY?
Since Jul 26, 2017, the NADAC for OLOPATADINE 665 MCG NASAL SPRY has ranged from a low of $0.7522 (May 22, 2024) to a high of $4.8968 (Sep 13, 2017), with a median of $1.2385 per GM.
Are there cheaper alternatives to OLOPATADINE 665 MCG NASAL SPRY?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as OLOPATADINE 665 MCG NASAL SPRY in a comparable dosage form, but none are currently priced below it.
Who manufactures OLOPATADINE 665 MCG NASAL SPRY?
OLOPATADINE 665 MCG NASAL SPRY (NDC 45802010401) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.